Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Gross Profit (2017 - 2020)

Historic Gross Profit for Ironwood Pharmaceuticals (IRWD) over the last 7 years, with Q4 2020 value amounting to $115.8 million.

  • Ironwood Pharmaceuticals' Gross Profit rose 42.94% to $115.8 million in Q4 2020 from the same period last year, while for Dec 2020 it was $386.4 million, marking a year-over-year increase of 2636.48%. This contributed to the annual value of $386.4 million for FY2020, which is 448.68% down from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Gross Profit of $115.8 million as of Q4 2020, which was up 42.94% from $103.5 million recorded in Q3 2020.
  • Ironwood Pharmaceuticals' Gross Profit's 5-year high stood at $115.8 million during Q4 2020, with a 5-year trough of $31.9 million in Q3 2019.
  • For the 4-year period, Ironwood Pharmaceuticals' Gross Profit averaged around $79.9 million, with its median value being $79.2 million (2017).
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Gross Profit crashed by 4167.58% in 2019 and then surged by 22441.21% in 2020.
  • Over the past 4 years, Ironwood Pharmaceuticals' Gross Profit (Quarter) stood at $85.2 million in 2017, then rose by 28.17% to $109.2 million in 2018, then rose by 5.55% to $115.3 million in 2019, then grew by 0.43% to $115.8 million in 2020.
  • Its Gross Profit was $115.8 million in Q4 2020, compared to $103.5 million in Q3 2020 and $89.4 million in Q2 2020.